At week 24, ALT normalization was reached by 53% of arm B and 38% of arm C (vs 6% of arm A, p, 0.0001). One patient treated with 2 mg BLV achieved an HBsAg reduction $1 log 10 IU/mL at week 24. Conclusion: This Phase 3 trial confirms that monotherapy with BLV is safe and well tolerated in patients with compensated cHDV infection. 24 weeks of treatment with BLV was associated with significant HDV RNA declines and improvements in biochemical disease activity. These findings further support the conditional approval of BLV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.